Payment overview · 2025
General Payments
$264.51
18 reported records · 6 companies
Healthcare provider profile · identity verified
Walker Eugene Nowell, DO
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1760428387
Verified facts
What the public records show
CMS Open Payments records show Walker Eugene Nowell, DO received $264.51 in general payments during 2025 across 18 reported records.
Novartis Pharmaceuticals Corporation accounted for 58.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $155.78 | 58.9% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.62 | 12.3% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $25.21 | 9.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.84 | 7.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.74 | 6.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.32 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $264.51 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $155.78 | 12 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $25.21 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
73 | 57 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 292 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 220 | 74 |
| Lisinopril | Lisinopril | 196 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 61 |
| Simvastatin | Simvastatin | 161 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 43 |
| Gabapentin | Gabapentin | 150 | 39 |
| Montelukast Sodium | Montelukast Sodium | 145 | 41 |
| Losartan Potassium | Losartan Potassium | 138 | 45 |
| Omeprazole | Omeprazole | 138 | 47 |
| Mounjaro | Tirzepatide | 125 | 23 |
| Trazodone Hcl | Trazodone Hcl | 123 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 35 |
| Metformin Hcl Er | Metformin Hcl | 115 | 36 |
| Alprazolam | Alprazolam | 107 | 24 |
| Bupropion Xl | Bupropion Hcl | 105 | 30 |
| Celecoxib | Celecoxib | 105 | 25 |
| Allopurinol | Allopurinol | 104 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 28 |
| Meloxicam | Meloxicam | 95 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 28 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 73 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 21 |
| Potassium Chloride | Potassium Chloride | 71 | 20 |
| Telmisartan | Telmisartan | 69 | 18 |
| Jardiance | Empagliflozin | 68 | 23 |
| Sertraline Hcl | Sertraline Hcl | 67 | 25 |
| Carvedilol | Carvedilol | 64 | 15 |
| Famotidine | Famotidine | 64 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 12 |
| Fenofibrate | Fenofibrate | 62 | 16 |
| Pregabalin | Pregabalin | 60 | 13 |
| Buspirone Hcl | Buspirone Hcl | 59 | 14 |
| Tramadol Hcl | Tramadol Hcl | 58 | 15 |
| Furosemide | Furosemide | 57 | 16 |
| Anastrozole | Anastrozole | 56 | 15 |
| Repatha Sureclick | Evolocumab | 56 | suppressed |
| Metformin Hcl | Metformin Hcl | 52 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 16 |
| Risedronate Sodium | Risedronate Sodium | 52 | 18 |
| Ramipril | Ramipril | 51 | 14 |
| Irbesartan | Irbesartan | 49 | 13 |
| Alendronate Sodium | Alendronate Sodium | 48 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Estradiol | Estradiol | 40 | 13 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 14 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 30 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | 12 |
| Ozempic | Semaglutide | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | 12 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 13 |
| Temazepam | Temazepam | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 26 | 26 |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 19 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Azelastine Hcl | Azelastine Hcl | 22 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Progesterone | Progesterone, Micronized | 20 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Eliquis | Apixaban | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $264.51 · 18 records | Novartis Pharmaceuticals Corporation | AREXVY, LEQVIO, NEFFY, Repatha, SHINGRIX, Veozah, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error